Baylor Genetics Incorporates Oxford Gene Technology’s SNP Array Probe Technology

Houston, Texas – Baylor Genetics has entered into an agreement with Oxford Gene Technology (OGT), The Molecular Genetics Company, to license the use of OGT’s proprietary single nucleotide polymorphism (SNP) array probe technology.

As part of the agreement, Baylor Genetics will utilize aCGH arrays containing both copy number variation (CNV) and SNP probes to identify a broad range of genetic syndromes. OGT’s intensity-based SNP probe technology provides an alternative to restriction enzyme-based approaches, which are unable to accurately analyze small amounts of DNA. The probes, designed by OGT, target each SNP allele, with the intensity ratio following hybridization allowing reliable detection of loss of heterozygosity (LOH).

Baylor Genetics’ Vice President of Operations, Sean Kim, says the relationship with OGT will enhance Baylor Genetics’ test offerings. “We are dedicated to the rapid delivery of the most accurate genetic analyses,” said Kim. “Through the application of OGT’s technology, we are now able to provide reliable array-based analysis of both copy number variation and loss of heterozygosity for challenging samples. We are now also looking to other areas of genetic analysis, expanding the use of this technology toward our complete portfolio.”

As a fully comprehensive approach to its genetic analysis strategy, Baylor Genetics will also utilize OGT’s Cytocell FISH probes, and following validation, will further expand the use of these probes.
“We are proud to be advancing the capabilities of such a prominent organization as Baylor Genetics with our SNP array probe technology and Cytocell FISH probes,” said Dr. Mike Evans, CEO of OGT. ”This presents just the first step in an ongoing relationship, and we look forward to continuing this close cooperation.”

About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The company’s Cytocell®, CytoSure™, and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.

For more information, please visit www.ogt.com.

Previous Post
Test Discontinuation Memorandum
Next Post
Test Discontinuation Memorandum
Menu